Phaseline

Companies › EicOsis Human Health

EicOsis Human Health: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 3 Phase 1; Neurology, Genitourinary; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
EC5026
Soluble epoxide hydrolase (sEH) inhibitor
EPHX2Phase 1Parkinson's Disease (PD); Chronic Kidney Disease; Spinal Cord InjuriesDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07142044EC5026Phase 1Parkinson's Disease (PD)NeurologyDec 2026
NCT07694544EC5026Phase 1Chronic Kidney DiseaseGenitourinaryDec 2026
NCT06438471EC5026Phase 1Spinal Cord InjuriesNeurologyDec 2027

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

EPHX2 (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.